am-2201 am-2201 am-2201 (1-(5-fluoropentyl)-3-(1-naphthoyl)indole) is a recreational designer drug that acts as a potent but nonselective full agonist for the cannabinoid receptor. it is part of the am series of cannabinoids discovered by alexandros makriyannis at northeastern university. am-2201legal statuslegal status ca: schedule ii de: anlage ii (authorized trade only, not prescriptible) nz: temporary class uk: class b us: schedule i identifiers iupac name 1--(naphthalen-1-yl)methanone cas number335161-24-5 ypubchem cid53393997chemspider24751884 yuniitbj0966f1ocomptox dashboard (epa)dtxsid50187158 chemical and physical dataformulac24h22fnomolar mass359.444 g·mol−13d model (jsmol)interactive image smiles o=c(c1=cn(cccccf)c2=c1c=cc=c2)c3=cc=cc4=c3c=cc=c4 inchi inchi=1s/c24h22fno/c25-15-6-1-7-16-26-17-22(20-12-4-5-14-23(20)26)24(27)21-13-8-10-18-9-2-3-11-19(18)21/h2-5,8-14,17h,1,6-7,15-16h2 ykey:alqfagfpqcbped-uhfffaoysa-n y ny (what is this?) (verify) hazards convulsions have been reported including at doses as low as 10 mg. pharmacology am-2201 is a full agonist for cannabinoid receptors. affinities are: with a ki of 1.0 nm at cb1 and 2.6 nm at cb2. the 4-methyl functional analog mam-2201 probably has similar affinities. am-2201 has an ec50 of 38 nm for human cb1 receptors, and 58 nm for human cb2 receptors. am-2201 produces bradycardia and hypothermia in rats at doses of 0.3–3 mg/kg, comparable to the potency of jwh-018 in rats, suggesting potent cannabinoid-like activity. pharmacokinetics